# US 2026/0283972 A1 · A compound for preparing lipid nanoparticles encapsulating an agent, nanoparticle composition comprising said compound and related methods thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0283972 A1
- Document ID: US20260283972A1
- Status: Published application
- Kind: A1
- Application number: 19/469,989
- Filed: 2024-03-27
- Published: 2026-09-24
- Earliest claimed: 2023-03-27
- Assignees: Agency for Science, Technology and Research
- Applicants: Agency for Science, Technology and Research
- Inventors: Yi Yan YANG; Jin Yan Melgious ANG; QiangQiang WANG; Zhengjie WU
- Web page: https://patentgrep.com/patent/US20260283972A1

## CPC

- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 9/5169: {Proteins, e.g. albumin, gelatin}
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61P 31/04: Antibacterial agents
- C07K 1/1077: {by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids}
- C07K 7/06: having 5 to 11 amino acids
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

There is provided a compound comprising a structure represented by general formula (1) or ionized forms thereof for preparing lipid nanoparticles encapsulating a cationic therapeutic and/or cationic prophylactic agent: wherein R1 and R2 are each independently a hydrophobic group; X comprises an optionally substituted linear aliphatic, optionally substituted branched aliphatic and/or optionally substituted cyclic hydrocarbons; and A comprises a peptide sequence of 1-5 anionic amino acids.

## Claims

### Claim 1

A compound comprising a structure represented by general formula (1) or ionized forms thereof for preparing lipid nanoparticles encapsulating a cationic therapeutic and/or cationic prophylactic agent:
wherein
R1 and R2 are each independently a hydrophobic group;
X comprises an optionally substituted linear aliphatic, optionally substituted branched aliphatic and/or optionally substituted cyclic hydrocarbons; and
A comprises a peptide sequence of 1-5 anionic amino acids.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the structure is represented by general formula (1A):
and wherein
R3′, R4′, R7 to R14 are each independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and combinations thereof;
m is 1, 2, 3, 4 or 5; and
n is 1, 2, 3, 4 or 5.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the hydrophobic group at R1 and R2 each independently comprises optionally substituted alkyl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is an ionized form of general formula (1).

### Claim 5 (depends on 2)

The compound of claim 2, wherein the compound is an ionized form of general formula (1A), where —C(═O)OR13 and/or —C(═O)OR14 has been ionized to become a negatively charged group.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the cationic therapeutic and/or cationic prophylactic agent comprises an antimicrobial agent.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the cationic therapeutic and/or cationic prophylactic agent comprises polymyxin.

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10 (depends on 1)

A nanoparticle composition for delivery of a cationic therapeutic and/or cationic prophylactic agent, the nanoparticle composition comprising:
a compound as claimed in claim 1; and
a cationic therapeutic and/or cationic prophylactic agent that is encapsulated in said compound as claimed in claim 1.

### Claim 11 (depends on 1, 10)

The nanoparticle composition of claim 10, wherein the charge ratio of the cationic therapeutic and/or cationic prophylactic agent that is encapsulated in the compound as claimed in claim 1 to said compound is from 1:1 to 10:1.

### Claim 12 (depends on 10)

The nanoparticle composition of claim 10, wherein the composition further comprises:
(a) helper lipid;
(b) sterol; and
(c) polyethylene glycol (PEG)-modified lipid.

### Claim 13 (depends on 12)

The nanoparticle composition of claim 12, wherein the cationic therapeutic and/or cationic prophylactic agent, helper lipid, sterol, compound represented by general formula (1), and PEG-modified lipid are mixed at a molar ratio of 10-120:3-30:10-130:2-30:0.5-10.

### Claim 14 (depends on 12)

The nanoparticle composition of claim 12, wherein the helper lipid is selected from the group consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), sphingomyelin and combinations thereof.

### Claim 15 (depends on 12)

The nanoparticle composition of claim 12, wherein the sterol is selected from cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, avenasterol and combinations thereof.

### Claim 16 (depends on 12)

The nanoparticle composition of claim 12, wherein the PEG-modified lipid is selected from PEG-modified phosphatidylethanolamines, PEG-modified phosphatidic acids, PEG-modified ceramides, PEG-modified dialkylamines, PEG-modified diacylglycerols, PEG-modified dialkylglycerols, or the like or combinations thereof. Examples of PEG-modified/PEGylated lipid include, but is not limited to, 2-[(polyethylene glycol)-2000]N,N-ditetradecylacetamide (ALC-0159), R-3-[(ω-methoxy-poly(ethylene glycol)2000) carbamoyl]-1,2-dimyristyloxlpropyl-3-amine (PEG-c-DOMG), 3-N-[(ω-methoxypoly(ethyleneglycol)2000) carbamoyl]-1,2-dimyristyloxy-propylamine (PEG-S-DMG), PEG-DMPE (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[(polyethylene glycol)-methoxy] (sodium salt)), PEG-DPPC, PEG-DSPE lipid and combinations thereof.

### Claim 17 (depends on 10)

The nanoparticle composition of claim 10, wherein the nanoparticle composition comprises nanoparticles having an average particle size of from 20 nm to 200 nm.

### Claim 18 (depends on 10)

The nanoparticle composition of claim 10, wherein the nanoparticle composition comprises nanoparticles having a zeta potential of from −20 mV to +20 mV.

### Claim 19 (depends on 10)

The nanoparticle composition of claim 10, wherein the nanoparticle composition comprises nanoparticles having a minimum bactericidal concentration (MBC) to minimum inhibitory concentration (MIC) ratio that is no more than 6.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23 (depends on 10)

A method of treating or preventing a disease, disorder or condition in a subject in need thereof, the method comprising administering a therapeutically effective amount of the nanoparticle composition as claimed in claim 10 to the subject, optionally wherein the disease, disorder or condition comprises bacterial infection.

### Claim 24

(canceled)

### Claim 25 (depends on 23)

The method of claim 23, wherein the disease, disorder or condition is mediated by Gram-negative bacteria.

### Claim 26 (depends on 25)

The method of claim 25, wherein the Gram-negative bacteria is selected from the group consisting of Escherichia coli, Pseudomonas aeruginosa, and combinations thereof.
